I2QVWIL01

```
1
      UNITED STATES DISTRICT COURT
      SOUTHERN DISTRICT OF NEW YORK
 2
 3
      JOHN WILEY & SONS, INC.,
      ET AL,
 4
                     Plaintiffs,
5
                 V.
                                               13 CV 816 (WHP)
6
      BOOK DOG BOOKS, LLC, ET AL,
 7
                     Defendants.
8
9
      CENGAGE LEARNING, INC., ET AL,
10
                     Plaintiffs,
11
                                              16 CV 7123 (WHP)
                 v.
12
      BOOK DOG BOOKS, LLC, ET AL,
13
                     Defendants.
                                           ARGUMENT
14
15
                                                New York, N.Y.
                                                February 26, 2018
16
                                                5:15 p.m.
17
      Before:
18
                        HON. WILLIAM H. PAULEY III,
19
                                                District Judge
20
                                 APPEARANCES
21
      OPPENHEIM ZEBRAK
22
           Attorneys for Plaintiffs
      BY: MATTHEW J. OPPENHEIM
23
      MANDEL BHANDARI
24
          Attorneys for Defendants
      BY: EVAN MANDEL
25
           ROBERT A. GLUNT
```

1	APPEARANCES (continued)
2	
3	GREENBERG TRAURIG
4	Attorneys for Miscellaneous Party Chegg, Inc. BY: NINA D. BOYAJIAN (appearing via telephone)
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

(Case called)

THE COURT: I'm going to deal with a number of matters here. I don't understand why every disagreement between the parties results in an urgent letter to the Court. I can tell you all that this is not the way the trial is going to proceed; that I've read some of these marathon sessions that you've had with Magistrate Judge Gorenstein. There are no more marathon sessions, okay? This is going to be a sprint to the finish for the jury. I'm going to set time limits on both sides for the trial, strict time limits, which I will enforce with a chess clock. And when your time is up, your case is over or your cross-examinations are over. Because it's about time that you understand that there have to be certain concessions to the mortality of man.

Now, the first dispute which I regard as emblematic of other disputes in this case is petty. It involves the plaintiffs' complaint about the number of witnesses that the defendants have identified. The defendants, quite properly, point out that they don't know precisely what the contours of the plaintiffs' case are and so it's just a protective mechanism. If the defendants want to waste their time during trial with duplicative testimony, at some point I'll just cut it off, because I don't want the jury bored to death.

Now, why, Mr. Oppenheim, are there still 1300 exhibits on the plaintiffs' list?

MR. OPPENHEIM: Your Honor, the defendants keep throwing that around.

THE COURT: You can remain seated and speak into the microphone because that will be the best way for counsel on the phone to hear the proceedings.

MR. OPPENHEIM: Very well. Habit, your Honor. Apologies.

Your Honor, of those 1300, 800 of them are just books and 150 of them --

THE COURT: Those 800 -- I'm not too worried -- those are cited in the roadmap, right, those books?

MR. OPPENHEIM: Certainly the counterfeits are. I'm trying to remember whether the legitimate exemplar --

THE COURT: I'm worried about the other 500 exhibits that are not referred to in the roadmap.

MR. OPPENHEIM: So 800 are the books, 150 are images of the books as backups, in part because we didn't know whether the defendants were going to bring the books within their possession. That now significantly reduces the number of exhibits at issue. Many of the other documents are just documents underlying the roadmap.

THE COURT: There's 161 works at issue, right?

MR. OPPENHEIM: Yes, your Honor.

THE COURT: Why do we need 800 exhibits for 100 -- why do we need 800 books for 161 titles?

MR. OPPENHEIM: Well, your Honor, first off, for each title at issue there's a counterfeit and there's a legitimate comparison copy. We will allow the jury to see some, but we're certainly not going to go through all of them, a handful of them for them to see because the defendants are contesting whether or not the books are counterfeit. So that's two for each. And for some of them there are just two.

THE COURT: But that takes us to 320.

MR. OPPENHEIM: Yes, your Honor.

In some instances there are multiples because they came from different places. So, for example, your Honor, the defendants have contested whether or not they distributed counterfeit copies of a particular title. And we may have received a counterfeit copy from Follett, a counterfeit copy from MBS, we may have gotten one from Chegg, we may have bought one from the defendants; and so we'll have — since they continue to contest whether or not they'll distribute it, we'll have multiple counterfeit copies, your Honor.

We'll move them in, your Honor, in bulk, assuming there's no objection, and they don't want us to go through each and every one of them. But we don't want there to be any argument later, Well, you didn't present that you got books from four different sources for a particular title. Your Honor, we have far more and we've tried to reduce it, but, your Honor, this kind of leads directly into the issue of

2

3

4

5

6

7 8

9

10 11

12

13 14

15

16

17

18 19

20

21

22

23

24 25

defendants' roadmap. We've tried to reduce the number that we are using. They then are using that against us to say that's the only -- those are the only counterfeits that the plaintiffs are aware of. We've only infringed that many books.

THE COURT: We're going to get to the motion in limine with respect to the defendants' roadmap in a few moments.

Mr. Mandel, on the witness issue, why do you need testimony from five third parties on counterfeit detection practices?

MR. MANDEL: As we said in the letter, your Honor, I would be surprised if we call more than two or three of those witnesses. That's really in there prophylactically. What we've got is we've got an expert who's going to testify as to market practices. That expert has been shown depositions from most or all of those parties. If we are satisfied at the end of the cross-examination of our expert on that market practice issue, we're very likely not going to call another distributor. Possibly we will call one or two more. The primary reason those five distributors are in there is because there are authenticity issues concerning documents or books produced by those parties in discovery, and the plaintiffs have already contested, such as with MBS, some of the evidence that we are putting in with respect to MBS.

I will also just finally globally note we were very surprised to see the plaintiffs' letter on the witness issue,

because we have identified 31 live witnesses and they have 1 2 identified 26 live witnesses. Unsurprisingly, those lists are 3 substantially the same. So we don't think there's any 4 prejudice whatsoever to plaintiffs, and we don't think there 5 was any basis for the letter in the first place. 6 THE COURT: Look, I'm going to jump ahead, in the 7 interest of counsel in California, and deal with the Chegg issue. And then, Ms. Boyajian, if you wish, after we've 8 9 disposed of that issue, you can just alert me as to whether or 10 not you want to remain on the conference call with the Court. 11 All right? Ms. Boyajian? 12 MS. BOYAJIAN: Yes, I said thank you, your Honor. 13 THE COURT: All right. 14 With respect to the Chegg summary, doesn't it really summarize a different set of evidence, Mr. Oppenheim? 15 MR. OPPENHEIM: I think you mean that question for 16 17 Mr. Mandel; correct? THE COURT: No. You object, don't you? You object to 18 the summary to the defendants' attempt to submit a summary of 19 20 data disclosed by Chegg. You say it violates Judge 21 Gorenstein's order, right? 22 MR. OPPENHEIM: Yes, your Honor. Sorry, I

THE COURT: My question to you is isn't this really a different set of evidence?

misunderstood your question.

23

24

25

MR. OPPENHEIM: Your Honor, what they are trying to do is put forward, whether you call it a roadmap or you call it a summary, right, essentially a counterweight to what the plaintiffs have put forward. Now, they are trying to substantially broaden the scope of it because they are going beyond titles and they are trying to look at the industry-wide — beyond the titles at issue and they are trying to look industry-wide. But they are essentially attempting to respond to the roadmap with this summary.

There was no deadline set, I will concede, for when summaries should have been presented. We put our summary forward in 2014, I believe, your Honor, maybe it was 2015. We have responded and adjusted it to issues that they have raised all along. They had an opportunity to take depositions of our witnesses about our roadmap. They have done nothing of the like; this came in very much at the very end, right after discovery is closed. Clearly Judge Gorenstein said to them, No — they asked Judge Gorenstein, Can we put other things in? And he said no. So they said, Okay, we are not going to call this a counter roadmap or a defendants' roadmap, we'll call this a summary and put it forward. But we haven't had a chance to address it.

The reason that's important here is because it really does attempt to do things very different than the roadmap. And so they are putting it in for very different purposes. It is

substantively problematic, your Honor.

THE COURT: All right. But why can't you cross-examine defendants on the problems that you note with this Chegg summary?

MR. OPPENHEIM: Your Honor, if they are going to start -- first off, the purpose that they want to use it for is to say, Look at the counterfeiting rate of defendants as compared to the counterfeiting rate of other distributors based on what the plaintiffs reviewed within that inventory.

The problem is that when the plaintiffs went in and reviewed Chegg inventory, it was very different sets of inventory. So the plaintiff said, Here are a specific set of titles that we know are likely counterfeited frequently that we want to look at for these, say, three or four different entities. But with respect to defendants, because we are in litigation with them, we want to see everything they've ever given to you. So it is not an apples—to—apples comparison.

For us to have to go through and explain that to the jury after they've put forward these numbers, which are absolutely not a fair statement. If you wanted to do a sampling, you could do a sampling. This is not a sampling. So they are trying to take Chegg data which is not theirs and use it for purposes it was not intended for to show something that it doesn't show.

If we had taken every book of every one of the other

distributors, we would have had a very, very low number for the other distributors as well, but we didn't. This is going to very much mislead the jury; it's not an appropriate use of that data.

Also, your Honor, 14 of the additional titles that are in there are titles that we want to raise. But your Honor has precluded us by saying that we can't. So, in other words, we've got infringements from the defendants after discovery closed, so 14 titles that are in the Chegg data. So if the Chegg data comes in and we get to cross-examine because you're allowing it in and we just go to the weight, then we should be allowed to raise the issue maybe it's just big-picture, maybe it's not handing actual infringing books up, but at least raise the issue, Well, at least with respect to 14 of those titles, we know the defendants infringed them as well and we've got evidence of it.

THE COURT: All right. Let me turn to the issue that concerns Chegg directly. I'm directing my inquiry now to you, Ms. Boyajian.

As I understand it, Chegg objects to this summary data because it identifies specific suppliers, and also mischaracterizes student buybacks, and also fails to reveal that it is, in fact — that the audit was only a subset of all of the books in the inventory of Chegg.

So turning to the first issue, the identity of

suppliers, what would Chegg's position be if the identities were simply changed to supplier one, two, and three?

MS. BOYAJIAN: That would certainly alleviate some of our concerns. The concern is with respect to the suppliers.

One is their actual identity, as your Honor knows; and the second is enforcing strategy. And by that, the books that we buy back --

THE COURT: I'm having trouble hearing you. What kind of phone are you on?

MS. BOYAJIAN: I'm on my landline, but I should pick up the receiver.

THE COURT: Yes, that makes a big difference.

MS. BOYAJIAN: Sure. Apologies.

I could start from the beginning of the argument, if your Honor would prefer.

THE COURT: I would.

MS. BOYAJIAN: Okay.

So the issue with the suppliers are twofold: The first is the identities, as your Honor notes. The second is the sourcing strategy, I'll call it. What I mean by that is a proportion of books that Chegg sources from one supplier as opposed to another, so what the volume is relative to — student buybacks relative to a large distributor such as MBS. And those are concerns that we have with respect to the suppliers, I think would be alleviated by what your Honor

suggests.

What would not be alleviated is what Mr. Oppenheim noted, which is that this number, the 17 percent number, grossly misrepresents what the counterfeit problem is in Chegg's inventory, which would cause significant reputational competitive harm to Chegg. That is not the actual proportion of counterfeits in our inventory, and it's so much larger that it is damaging to our reputation.

THE COURT: How does it misrepresent the proportion of books in Chegg's inventory?

MS. BOYAJIAN: As Mr. Oppenheim explained, when the publishers came to us to do the audits, they have specific titles that tended to have higher rates of counterfeit. And they selected those titles to audit.

I was not 100 percent sure until Mr. Oppenheim made the representation just a moment ago that with respect to defendants, they audited the entire inventory, which is why our number is 16 or 17 percent higher than their number. It was not a pure sampling, a typical sampling, a random sampling, if you will.

THE COURT: All right.

Mr. Mandel, how does this summary make any sense then when different standards were used for each supplier?

MR. MANDEL: First of all, we don't know what the standards that were used. All we know is that Mr. Oppenheim's

firm chose which books to review. We have not deposed Mr. Oppenheim's firm on this issue; although there are a variety of issues we could have deposed Mr. Oppenheim's firm on, we chose not to do so because we didn't want to slow down this case or interfere with it and that's just not how we practice when there's any way to avoid it.

We don't know that this is the case, Mr. Oppenheim's firm had sole decision-making with respect to which books were and were not inspected. To the extent that some different standard was used, that has nothing to do with the admissibility of the evidence. If anything, it goes to the weight of the evidence. If they want to respond and say, Well, actually — and what they say in their papers is that if you did the analysis, if you looked at the defendants' books that are only the titles at issue in this case, it would be, in their words, a 500 percent higher percentage for the defendants. "500 percent" is a fancy way of saying five times more.

If you look at these numbers and you say, Our number is five times higher than it really is, that still shows that our numbers are a tiny fraction of the Chegg figure, and substantially in line with the two major distributors that are on here, and we'd still compare favorably to everyone else on the chart, with one exception.

So even if you looked at these numbers the way the

plaintiffs are asking the Court to look at it — and we have no reason to believe that they should be looked at the way plaintiffs are asking, but that's what they say — then it still shows that, one, when they went into MBS and pulled a book off the shelf, it was no more likely to come from us than it was to come from a buyback or Chegg or the other distributors that are listed on this list. And, two, if it did ultimately come from us when they pulled a random book off MBS's shelf and then sued us claiming it came from us, that we didn't distribute it willfully, because our percentages are no higher than these other distributors.

MBS, for instance, was deposed in this case. The plaintiffs share a ton of information with MBS; they've trained MBS's personnel in how to detect counterfeit books. Plaintiffs don't share any information with us. Plaintiffs have never trained us on how to detect counterfeit books; yet we are just as good, if not better, than MBS at detecting counterfeit books and removing them from our inventory, according to their reading of the numbers.

So this is extremely persuasive evidence, even if it's interpreted in the way that plaintiffs ask for it to be interpreted, and it is absolutely mission critical for this case, which the Court has already ruled on.

MS. BOYAJIAN: Your Honor, if I may be heard.

Mr. Mandel's argument doesn't at all address Chegg's

confidentiality concerns. And while defendants and plaintiffs are in a position to argue persuasiveness and reputation and what a counterfeit rate might mean for defendants, Chegg is not in that position. We're going to have our confidential information paraded out in front of our potential consumers without any opportunity to explain our position and our procedure in the policies.

MR. OPPENHEIM: Your Honor, may I --

THE COURT: Go ahead, Mr. Oppenheim.

MR. OPPENHEIM: This doesn't speak to what the defendants are buying and selling generally. This speaks to what they sold to Chegg, compared to what other distributors sold to Chegg. The number of books that they sold to Chegg was smaller than the other distributors. Chegg may rely much more on other distributors. It doesn't mean anything. In fact, the defendants sell a huge number of their books through their online system, Apex Media, and Chegg isn't buying them through there or, if they are, they are not being marked as defendants.

So this isn't representative of what the defendants are doing, this is just representative of what Chegg has received from the defendants. And to use it as a proxy to say, We're not willful because look at how less egregious our infringement is compared to others, that's exactly the kind of argument that a jury should never hear. This just shows what they're selling Chegg.

This case should be about the books that we've reviewed that have come from the defendants, what they are doing internally, what they've distributed, not what Chegg has bought from the world and what Chegg's operations happen to have found and what a statistically odd sampling process for different distributors into Chegg showed. That's not what this case should be about.

THE COURT: All right.

Mr. Mandel, I'll think about this a little further, but I tell you that I think that this summary is highly misleading, because it's clear that different standards were used, and it's argumentative. But I don't want to hear -- I've heard enough on it. I'll think about it some more, but I'm going to -- and I'll issue an opinion.

Now, let me turn to the MBS summary.

MS. BOYAJIAN: Your Honor, before your Honor proceeds, may I disconnect from the call?

THE COURT: You may.

MS. BOYAJIAN: Thank you.

THE COURT: Have a good afternoon.

MS. BOYAJIAN: Good afternoon.

THE COURT: With respect to plaintiffs' motion in

limine on the MBS summary, Mr. Oppenheim, Judge Gorenstein

specifically allowed the defendants to offer a counter roadmap.

I don't understand your argument as to how they waived the

right to do so.

MR. OPPENHEIM: Yes, your Honor.

So that's the procedural issue we've raised; we also had a substantive issue.

But procedurally, your Honor, back in 2015, the defendants indicated they had objections to plaintiffs' roadmap and that there were issues they wanted to raise with it. And we said fine. And we had a meet-and-confer with Ms. Miller, their counsel of record at the time, lead trial counsel. We agreed upon a process. They designated a witness who was going to be their witness to state their objections to the roadmap and what was not included in the roadmap. And we said, Fine, we'll take his deposition.

We went to take his deposition; Mr. Mooney defended him. And at the deposition they said — they stopped us from asking questions about his objections to our roadmap and said they were going to put forward their own version, so we should just wait until they did that. So we didn't follow through with the rest of the deposition and we waited. And we kept sending emails, where is it, right, we want to get it, move the process forward. And then Ms. Miller came back and said unequivocally, You should have no continuing expectation to receive a document of that nature; they have no intent on putting forward a counter roadmap.

We said okay.

So it didn't happen.

Now, it's not as though that part of the litigation just doesn't matter anymore because Mr. Mandel's firm is now involved. We did what we were supposed to do. They raised objections; we created a process to address their objections; they did an about-face midway through the deposition, which was a little frustrating, but we dealt with it on the fly. They said they were going to put up something; we said okay.

I'm not sure what else we could have done, your Honor, but I think that you can't just erase it and say that didn't happen. There's a very clear record where they said they weren't going to put it forward, and that should mean something. Judge Gorenstein was unaware of this record at the time because the issue had not arisen before Judge Gorenstein. But the record, it really couldn't be clearer.

For the defendants to say it was part of a settlement dialogue, it wasn't at all. Does it sound like settlement dialogue? It wasn't at all; it was all part of a roadmap discussion. And they said, No, we are not putting one forward.

And then to come after discovery is closed, very late in the game, and put forward this counter roadmap, which, by the way, has all kinds of issues, and I would like to walk through the substantive issues with your Honor if we need to, but for them to now put it in on the eve of trial, it's just wrong, your Honor. It's as though what we did two years ago is

irrelevant, and that can't be the case. 1 2 THE COURT: Mr. Mandel. 3 MR. MANDEL: Two points, your Honor. 4 First, it's not a counter roadmap. There are 161 5 titles at issue in this case. This document does not purport 6 to have anything to do with all 161 titles; instead, all it 7 does is summarize two spreadsheets that MBS produced. So there's no way to construe this as some sort of counter 8 9 roadmap. 10 THE COURT: First of all, you can call it whatever you 11 want, okay, it is a counter roadmap. It's 41 titles or so that 12 came from MBS that are involved in this litigation, right? 13 MR. MANDEL: Correct, your Honor. 14 Okay. Isn't it incredibly misleading? THE COURT: 15 MR. MANDEL: I don't think it's misleading at all, 16 your Honor. 17 THE COURT: How can you take the plaintiffs' number of alleged counterfeits, which are exemplars, and say that that's 18 the total number of counterfeits? 19 20 MR. MANDEL: To be clear, your Honor, those are not 21

MR. MANDEL: To be clear, your Honor, those are not exemplars. In this case those are the total number of books that plaintiffs have educed any evidence whatsoever were counterfeit. They went to MBS; they pulled two books off the shelf, for instance; they studied those two books. They gave us an expert report that said, These two books are counterfeit.

22

23

24

25

That is our evidence that you sold a counterfeit copy of this particular title, and that's the basis of our liability claim for copyright infringement here.

THE COURT: But plaintiffs never argued -- nor do they need to -- that those are the only specific copies that were counterfeit.

MR. MANDEL: I don't know if they have sufficient evidence to make the argument to the jury that any more than those two books are counterfeit. This information is no different than the information that's in their roadmap. They only identify — where there's two titles, where there's two books that they have provided expert testimony on, their roadmap says there's two books here, here are the books, take a look at those books, and identifies them by exhibit number.

THE COURT: Mr. Oppenheim?

MR. OPPENHEIM: I think it would be useful, your Honor, to look at a particular page.

THE COURT: Go ahead.

MR. OPPENHEIM: So if you're looking at Exhibit B of our motion in limine, your Honor, and turn to title 10B, as in boy.

THE COURT: Just hang on one second.

MR. OPPENHEIM: Sure.

THE COURT: Can you work with the summary of data disclosed by MBS?

MR. OPPENHEIM: If you could turn to the actual page, your Honor, I think that would help.

THE COURT: All right. Give me the page number.

MR. OPPENHEIM: It's title 10B. They don't have page numbers, but the title is called, ironically, "Business Ethics."

THE COURT: All right. I've got it.

MR. OPPENHEIM: Your Honor, let's look at this for a moment.

So the ISBN is right. The number of alleged counterfeits they say is one. Here's the evidence that we've presented that we know of for a certainty: We know and have presented to them a copy of a book that they've had an opportunity to review from MBS that has the defendants' sticker on it. They have seen another copy from MBS that does not have the sticker on it. They have seen records that show they bought 100 copies of this from Best Books World, who they, on at least three different instances on their own internal communications, indicated was a counterfeit supplier. They've also acknowledged that they don't have clear records of all of the purchases from Best Books World.

So to put forward to a jury that the plaintiffs are claiming that the defendants only sold one copy of this, A, it's wrong; and, B, it's misleading. We have no idea how many counterfeit copies of "Business Ethics" the defendants sold,

but we have certainly given them evidence of far more than one.

And then they carry that problem down from the number of alleged counterfeits down to the percentage of defendant sales alleged to be counterfeit, because that number is just derivative of the one. So they've exacerbated the problem and then carried it over to percentage of counterfeits alleged to come from defendants to .34, all on this -- it's all built on a foundation which is false, your Honor. The only thing in here that could possibly come from the MBS data is the books purchased from defendants and books purchased from other distributors. But that's only for MBS.

MR. MANDEL: Your Honor, with respect to the fields at the top of this page, we copied that information from plaintiffs' roadmap. That is just background information that is designed to help the jury understand precisely what is going on. I think it's entirely appropriate. I don't think it can be prejudicial to the plaintiffs in any way since the same information is on their roadmap. And if they've got a summary, we should be allowed to use the exact same information on our summary.

However, if the Court is particularly concerned with these issues that Mr. Oppenheim is raising, what is mission critical to the case is the summary of the two MBS spreadsheets. I know that, so the record is clear, at the Court's request, we forwarded copies of those spreadsheets to

the Court this morning via email. Those spreadsheets are impossible to understand without some kind of summary. And although I don't think there's any basis for doing this, if the Court finds the specific pages of the roadmap that go — or the pages of the MBS summary that go title—by—title to be problematic in some way, then the spreadsheet at the beginning of the MBS summary data provides the absolutely mission critical information.

So going to 10B, "Business Ethics," there's a title page called "MBS Titles by the Numbers," and then I'm on the following page. And if you go to 10B, it says, Alleged counterfeits from defendants, one. And then it says, Total purchases from defendants, 17. That's the total number that MBS purchased from defendants. Total purchases of this title from others, that's 6,035. Total counterfeits found at MBS, that's 291.

We've submitted a revised version of this that addresses some of the plaintiffs' concerns about numbers, but then the last column is defendants' sticker on alleged counterfeits, and then there's a yes or no just to provide that information.

Obviously this data is most important for the books for which there was no sticker on. Those are books that plaintiffs just pulled off the shelf at MBS, and they are asking the jury to draw an inference on the basis of

circumstantial evidence that defendants are the one who sold that book that they pulled off the shelf at MBS to MBS.

As the Court will recall during the summary judgment briefing, we argued that without the numbers that are in the spreadsheet here, without knowing how many copies MBS purchased from defendants, and how many copies MBS purchased from others, and how many copies on the shelf were found to be counterfeit, it's impossible to find by a preponderance of the evidence that it's more likely than not that we sold MBS that book. We said you need both a numerator and a denominator in order to make that analysis.

(Continued on next page)

MR. MANDEL: Judge Gorenstein agreed with us and dismissed virtually every single claim that was based on circumstantial evidence.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

THE COURT: Are you suggesting getting rid of all the individual title-by-title pages?

MR. MANDEL: I'm saying that if your Honor is concerned with the individual title-by-title pages, either because it makes it appear more similar to the plaintiff's roadmap or because the Court doesn't like some of the specific fields in that thing, what is mission critical from our perspective is making sure that the jury has access to both the numerator and the denominator. I think there's a purer -- your Honor of course disagreed with Judge Gorenstein on this issue on summary judgment and brought the 117 titles that are based on circumstantial evidence back into the case. But what there is, if this evidence is excluded, is a pure question of law, which is, if this numerator and denominator information isn't provided to the jury, can a jury ever find that it's more likely than not that we sold that book to MBS. I know that Judge Gorenstein came out one way on that issue, your Honor reversed Judge Gorenstein, but if this information is included, it makes it much easier for the jury to address this issue, and as the Court has seen the spreadsheet, the spreadsheet -- the two spreadsheets that MBS produced are impossible to understand without a summary, and it's the kind of document that is

screaming for a summary to be provided.

THE COURT: I'll tell you that the title-by-title pages are very misleading. For instance, you characterize them as counterfeit when they just had counterfeit characteristics. You're substituting your own loaded terms, not summarizing the spreadsheet.

So Mr. Oppenheim, what about getting rid of all the individual title-by-title pages?

MR. OPPENHEIM: So your Honor, certainly that addresses one aspect of the substantive issues, but there are two other issues on that.

But before I go to it, it's critical to understand as a background, your Honor, that what they deem as circumstantial evidence and that the jury could never possibly tell whether or not the counterfeit books came from the defendants or not is so misleading. The records will show that they bought the books from a known counterfeit source, they sold them on sometimes the exact same day or within days, the same quantity to MBS.

MBS then had counterfeits in their inventory, they turned them over. We asked the MBS witnesses: Do you believe this came from the defendants? Yes, they do. So it's not as though there's no record and the jury can decide and they can make their arguments. So the arguments are there without these numbers.

But let me turn to the two substantive issues on this.

The first is that, I'm very confused. They fought vigorously and said they were going to call, as an expert witness, Professor Wu, who did a statistical analysis of this. Now we thought Dr. Wu's analysis was weak and should not be admitted, and we said as much in our motion in limine. We lost that, your Honor, but if they're bringing Dr. Wu, who did a statistical analysis on this, to then do this as well seems to be loaded for bear against us, your Honor, on presenting the evidence two different ways. This way, your Honor, it's not calculated right, and we can't figure it out why.

And let me explain that to you. And I have to go back historically. We received this MBS data in BDB-I. The plaintiffs, we did not ask the deponent about these spreadsheets because they're really, as compared to the other things we were asking the witness, not relevant. The defendants chose not to examine MBS on the underlying data spreadsheets either. They never asked any questions. So the case goes on. They bring this expert in who doesn't understand — he only understands what the data is from talking to the defendants. That raises other issues, your Honor. But so be it. They realize, oh, no, we may have an issue with this.

After discovery is closed, they go to Judge Gorenstein and they say, your Honor, in BDB-II, there are four titles that came from MBS, and even though discovery is closed, we'd like

to take MBS's deposition. And Judge Gorenstein issues an order, which you can't tell from the transcript likely he agonized over it during one of those marathon sessions, and he said, you know what, I'm going to let you do it, but this deposition is limited to those four titles and those four titles alone, and nothing else. And you'll do it telephonically, and you'll patch, you know — so on and so forth.

They turned around and went to MBS and they said, if you give us a 902(11) certification, on BDB-I, we won't take your deposition on these four titles. So MBS does that.

Your Honor, I think that's improper. Can I cite a rule that says it's improper? No. I think it's improper. But I ask you to turn to Exhibit O and look at the 902(11) certification to see what the problem is here, your Honor.

THE COURT: The problem is Appendix B.

ATTORNEY O: Yes. Well, sorry, your Honor. Yes.

Well, and the explanation of it in the declaration, your

Honor — in the certification, your Honor. It's hearsay. And

when the defendants, in doing their analysis for purposes of

their roadmap, defendant's roadmap, counter roadmap, summary,

whatever you want to call it, the MBS analysis, all they did is

look at the books coming in. They didn't look at the books

that went out. So if there was a restock or a return or some

other change in status by virtue of one of these adjustments,

they didn't look at it. Your Honor, I don't know what effect that has, because I don't understand what each of these things is. But the way you would figure that out is in a deposition, where you would talk to the witness. But discovery is closed. They did this after discovery closed. We can't go and ask them to understand it. So we can't tell whether these numbers are right or not. All we know is that they only looked at incoming, they didn't look at outgoing.

THE COURT: What if I ordered it?

MR. OPPENHEIM: Two weeks before the trial, your Honor? Because of all of the new things that keep getting turned over last minute, we're already struggling to get ready for this trial, your Honor. And you've kicked this trial several times, which it should be a lot easier, but we're getting documents we should have gotten five years ago, your Honor. So yes, you could order it, but then we're going to sit there and they're going to do a data analysis, they're going to produce another summary, I'm going to have to have somebody go through all the numbers and check whether they're right, and we're going to meet and confer and correct it. That's a huge amount of time when we should be narrowing our case and getting our witnesses ready to put on a very succinct trial.

THE COURT: Mr. Mandel, how is Appendix B to the 902 certification appropriate?

MR. MANDEL: Appendix B is just a description of the

fields.

THE COURT: It's testimonial, isn't it?

MR. MANDEL: I would disagree with that, your Honor.

I think it's -- they produced the spreadsheet. It's simply,
they --

THE COURT: It interprets a business record, doesn't it?

MR. MANDEL: Well, there were column headings on it, and those column headings were shorthand for information. All they're telling you is what the full name of those column headings are. They could have written the entire description on those column headings. But to sort of focus the big picture issue here, have plaintiffs somehow been prejudiced by the way all of this occurred? And the answer is, absolutely not. They admit that they had this document before MBS's deposition in Book Dog Books I. Had they had concerns they wanted to raise at that time and they wanted to ask the witness about the document, they could have done so.

Second, they have identified MBS as a live trial witness. MBS is owned by Barnes & Noble. It's a wholly-owned subsidiary. Barnes & Noble is headquartered in New York. It's clearly subject to the court's subpoena power. And they're going to, if either party would like, appear here at trial. No deposition is necessary. They can provide this testimony live on the stand.

Third, I will say, according to the plaintiffs, MBS has signed on to plaintiff's best practices. And those best practices require MBS to cooperate with the plaintiffs in their anticounterfeiting investigation. Presumably that cooperation includes not just providing documents, which they have done voluntarily throughout these cases to MBS, to the plaintiffs, but it also includes testifying, which they also did — they were willing to do in both cases. So I have no doubt whatsoever that if the plaintiffs need additional information from MBS, either they've already obtained it or they'll have no difficulty obtaining it voluntarily, and if not, they can subpoena MBS to testify at this trial.

THE COURT: All right. Let me turn to one final issue: The declarations that are cited in the plaintiff's roadmap.

First, I've reviewed the defendant's objections to the exhibits cited in the plaintiff's roadmap, all 772 of them. I can tell you that I'm not persuaded by any of those objections other than the objections that are raised with respect to Plaintiff's Exhibits 63, 73, and 84, which are the declarations. Who are these individuals, Mr. Oppenheim, and how did the plaintiffs get in touch with them?

MR. OPPENHEIM: So your Honor, during the course of BDB-I, at some point we became aware of certain titles having been sold by the defendants to certain customers and that they

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

had come from a known counterfeit source, and we reached out to those individuals and asked whether we could buy the book back from them when they were done with it, or something to that effect. And a handful of them responded and they sent us the books, and they were in fact counterfeit. It confirmed -- the defendants were saying, well, just because you found something in our inventory or just because it was sold to us by a counterfeit supplier, you can't show that it was actually distributed. So this was a way for us to identify that these books had actually been distributed to these sources. And they signed declarations, and we reviewed the books, and we made it all available to the defendants so that if they wanted, they could take these people's deposition if they wanted, they could look at the books if they wanted. They had access to all of it for several years now. And it just further supports the existing claims, your Honor.

THE COURT: Did any of these individuals, these three individuals receive any compensation?

MR. OPPENHEIM: I think we gave them a \$10 Starbucks card, your Honor.

THE COURT: And the defendants were afforded an opportunity to depose them?

MR. OPPENHEIM: They've had these -- we produced them immediately in BDB-I, your Honor, so they've had them for several years.

THE COURT: All right. Mr. Mandel, what factors weigh against admitting these declarations under the residual exception? I mean, they're pretty cut and dry, aren't they?

MR. MANDEL: I don't have them in front of me and I didn't know this was going to be discussed. I've read them some months ago.

THE COURT: Well, as I say, out of the 772 objections that were lodged, there's only three that attracted my attention. I'm overruling all the other ones.

MR. MANDEL: I understand, your Honor. You know, I don't know if they ever identified in BDB-I these individuals as witnesses. They were on their 26(a) disclosure. Unless and until they're identified on their 26(a) disclosure, there's no reason for the defendants to depose them. But as a general matter, and in my experience, courts do not entertain the admissibility of declarations at trial. So it would not have occurred to me that I needed to depose someone just because the other side produced a declaration. If they wanted testimony from that person, they will produce that person at trial and I'll be able to cross-examine that person at trial. I understand that depositions are common in civil practice, but they're not required, and you're allowed to confront witnesses at the trial.

So for all those reasons, I don't think the declarations should come in.

THE COURT: Well, do you have anything to suggest that they're faulty or in some fashion fraudulent?

MR. MANDEL: We have no idea how these people were compensated.

THE COURT: He just said they got a \$10 Starbucks card.

MR. MANDEL: Actually, your Honor, he said two different things that were inconsistent with each other. First he said that they offered to buy the books back from them and then later, when your Honor asked about compensation, he said it was a Starbucks card. So it's not clear to us from what we've heard whether they offered to buy — they actually bought them back and, if so, at what price did they buy them back; and two, we don't know about these Starbucks cards. So I think there's a compensation issue.

Second, it's not clear -- you know, the way students behave, it's not entirely clear that at the end of the semester every student winds up with the book they had at the beginning of the semester. You're in a class with possibly hundreds of other people, you're studying with other people, and had there been a deposition or if there's going to be trial testimony, we would inquire as to whether they're sure that they didn't swap books with their roommate or their classmate or whatever. And the issue is an authenticity issue.

MR. OPPENHEIM: Your Honor, to the issue of

communications with these witnesses, we turned over all of them, so the letter that says the \$10 Starbucks card, they have all those communications. They have everything. They've had them for years.

THE COURT: Did you buy back the books?

MR. OPPENHEIM: Actually, I think we gave them another copy. We swapped out, gave them another copy of the book, and took the one that they had, and then gave them a \$10 Starbucks card on top of it. That's my recollection. I don't have the documents right in front of me, your Honor, but they have them. They also provided to us, your Honor, the documents showing they bought the books from the defendants. So we contacted the individuals, they say yes, I bought it from the defendants, here's my Amazon receipt, here's the book, and, you know, so they're free to argue, well, you don't know that maybe it was swapped in the classroom. They're free to make that argument to the jury. I don't think anybody's going to believe it, but they can make it.

THE COURT: All right. Counsel, I think I've heard enough. I'll issue some short orders on these outstanding issues in the next week or so, during the hours of the day when I'm not trying a criminal case.

MR. OPPENHEIM: Very well, your Honor. May I ask -- I'm sorry.

THE COURT: Yes.

I2q1joha2 MR. OPPENHEIM: Would it be all right for us to 1 2 coordinate with your clerk on the issue of bringing evidence 3 into the courtroom for the purposes of the trial? 4 THE COURT: Yes, of course. All right. That will be 5 fine. And any equipment that you want to bring in or any electronic devices, submit orders to me. But be parsimonious 6 7 about the number of electronic devices that you want to bring in because recently I had a matter where lawyers had 20 people 8 9 bringing in a variety of devices, and I said fine, two people 10 bringing in just a couple devices. Because that's not going to 11 get past the security committee, and I wouldn't even purport to 12 sign off on something like that. All right? 13 MR. OPPENHEIM: Very well, your Honor. 14 15 cellphone in here or another device. 16 17 Have a good evening.

THE COURT: And that means attorneys in the case or people in your firm, not clients. Okay? Clients can't bring a

ALL COUNSEL: Thank you, your Honor.

THE COURT: Decision reserved.

THE DEPUTY CLERK: All rise.

21 000

22

18

19

20

23

24

25